- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02259894
Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers
October 7, 2014 updated by: Boehringer Ingelheim
Safety, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BIRT 2584 XX (5, 30, 100, 200, 350, 500, and 700 mg) as a Solution in PEG 400 Administered to Healthy Male Volunteers. Placebo Controlled and Blinded at Each Dose Level.
To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BIRT 2584 XX in single rising oral doses of 5 mg to 700 mg in a polyethylene glycol 400 (PEG 400) solution in healthy subjects
Study Overview
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects as determined by results of screening
- Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- Age >=18 and <=50 years
- BMI >=18.5 and <=29.9 kg/m2
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Relevant history of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- Use of any drugs, which might influence the results of the trial, (< 10 days prior to study drug administration or expected during the trial)
- Participation in another trial with an investigational drug (< 2 months prior to administration or expected during trial)
- Smoker (> 10 cigarettes or >3 cigars or >3 pipes/day)
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation or loss > 400 mL, < 1 month prior to administration or expected during the trial
- Clinically relevant laboratory abnormalities
- Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 110 ms or QT interval, Bazett correction (QTcB) > 450 ms or QT interval >500 ms
- Inability to comply with dietary regimen of study centre
- Inability to comply with investigator's instructions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIRT 2584
single rising doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: Up to 16 days after drug administration
|
Up to 16 days after drug administration
|
Number of participants with clinically significant changes in vital signs
Time Frame: Up to 16 days after drug administration
|
Up to 16 days after drug administration
|
Number of participants with abnormal changes in clinical laboratory parameters
Time Frame: Up to 16 days after drug administration
|
Up to 16 days after drug administration
|
Number of participants with abnormal findings in 12-lead ECG (electrocardiogram)
Time Frame: Up to 16 days after drug administration
|
Up to 16 days after drug administration
|
Number of participants with abnormal findings in physical examination
Time Frame: Screening and up to 16 days after drug administration
|
Screening and up to 16 days after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (maximum concentration in plasma)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
tmax (time from dosing to maximum concentration)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 extrapolated to infinity)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 to the last quantifiable analyte plasma concentration)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
λz (terminal rate constant in plasma)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
t1/2 (terminal half-life of the analyte in plasma)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
MRT(mean residence time of the analyte in the body)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
CL/F (apparent oral clearance in plasma after oral administration)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
Vz/F (apparent volume of distribution during the terminal phase λz) dose)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
Ae0-48 (amount of analyte that is eliminated in urine from 0-48 hours)
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
fe0-48 (fraction of analyte eliminated in urine from 0-48 hours)
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
CLR,0-48 (renal clearance of the analyte from 0-48 hours)
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Receptor occupancy as determined by binding of anti-LFA-1 antibody fragment (Fab)
Time Frame: Up to 360 hours after drug administration
|
Up to 360 hours after drug administration
|
|
Inhibition of IL-2 production
Time Frame: Up to 360 hours after drug administration
|
in response to superantigen challenge ex vivo
|
Up to 360 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Primary Completion (Actual)
June 1, 2004
Study Registration Dates
First Submitted
October 7, 2014
First Submitted That Met QC Criteria
October 7, 2014
First Posted (Estimate)
October 9, 2014
Study Record Updates
Last Update Posted (Estimate)
October 9, 2014
Last Update Submitted That Met QC Criteria
October 7, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1206.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy